These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16752937)

  • 1. Long-term treatment with atypical antipsychotics and risk of weight gain.
    Stip E; Anselmo K; Wolfe M; Lessard C; Landry P
    Drug Saf; 2006; 29(6):550-2; author reply 552. PubMed ID: 16752937
    [No Abstract]   [Full Text] [Related]  

  • 2. Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain.
    Karagianis J; Hoffmann VP; Arranz B; Treuer T; Maguire GA; de Haan L; Chawla B
    Hum Psychopharmacol; 2008 Jun; 23(4):275-81. PubMed ID: 18338426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
    Cañas F; Möller HJ
    Expert Opin Drug Saf; 2010 Sep; 9(5):683-97. PubMed ID: 20690885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The appearance of metabolic syndrome in treatment with atypical antipsychotics].
    Mosolov SN; Kabanov SO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):62-9. PubMed ID: 14681970
    [No Abstract]   [Full Text] [Related]  

  • 5. Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects.
    Joseph E; Reddi S; Rinwa V; Balwani G; Saha R
    Eur J Pharm Sci; 2017 Jun; 104():315-325. PubMed ID: 28408348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic drugs and schizophrenia.
    Duan N; Kraemer HC; Mintz J
    N Engl J Med; 2006 Jan; 354(3):298-300; author reply 298-300. PubMed ID: 16422019
    [No Abstract]   [Full Text] [Related]  

  • 7. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course.
    Gebhardt S; Haberhausen M; Heinzel-Gutenbrunner M; Gebhardt N; Remschmidt H; Krieg JC; Hebebrand J; Theisen FM
    J Psychiatr Res; 2009 Mar; 43(6):620-6. PubMed ID: 19110264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight change and atypical antipsychotic treatment in patients with schizophrenia.
    Jones B; Basson BR; Walker DJ; Crawford AM; Kinon BJ
    J Clin Psychiatry; 2001; 62 Suppl 2():41-4. PubMed ID: 11232752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expectations and developments in atypical antipsychotics].
    Praxis (Bern 1994); 2004 Aug; 93(35):1392. PubMed ID: 15468579
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate.
    Lin YH; Liu CY; Hsiao MC
    Psychiatry Clin Neurosci; 2005 Oct; 59(5):613-5. PubMed ID: 16194268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine and weight gain.
    Isaac MB; Isaac MT
    Am J Psychiatry; 2005 Sep; 162(9):1764-5; author reply 1765. PubMed ID: 16135655
    [No Abstract]   [Full Text] [Related]  

  • 12. Bofu-tsusho-san effectively attenuates the weight gain observed after receiving olanzapine.
    Yamamoto N; Inada T
    Psychiatry Clin Neurosci; 2008 Dec; 62(6):747. PubMed ID: 19068015
    [No Abstract]   [Full Text] [Related]  

  • 13. Unusual suspect for antipsychotic-induced diabetes.
    O'Neill MF
    Drug Discov Today; 2005 Oct; 10(20):1338. PubMed ID: 16253867
    [No Abstract]   [Full Text] [Related]  

  • 14. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is olanzapine a brain-sparing medication?
    Joober R; Schmitz N; Malla A; Sengupta S; Karma S
    Arch Gen Psychiatry; 2006 Nov; 63(11):1292. PubMed ID: 17088510
    [No Abstract]   [Full Text] [Related]  

  • 16. Polymorphisms of the histamine receptor (H1HR) gene are not associated with olanzapine-induced weight gain.
    Godlewska BR; Olajossy-Hilkesberger L; Olajossy M; Limon J; Landowski J
    J Clin Psychopharmacol; 2013 Jun; 33(3):436-7. PubMed ID: 23609395
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
    Houston JP; Kohler J; Bishop JR; Ellingrod VL; Ostbye KM; Zhao F; Conley RR; Poole Hoffmann V; Fijal BA
    J Clin Psychiatry; 2012 Aug; 73(8):1077-86. PubMed ID: 22967772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness criterion: balancing efficacy against the risks of weight gain.
    Citrome L
    J Clin Psychiatry; 2007; 68 Suppl 12():12-7. PubMed ID: 17956151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight gain due to long term antipsychotic treatment of persistent mental disorders.
    Tadger S; Melamed Y
    Psychiatr Danub; 2008 Mar; 20(1):37-41. PubMed ID: 18376329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report.
    Markham-Abedi C; de Leon J
    J Clin Psychiatry; 2006 Sep; 67(9):1473-4. PubMed ID: 17017841
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.